Top Companies in Vascular Access Devices Market

The global vascular access device (VAD) market is projected to grow from USD 6.29 billion in 2026 to USD 8.70 billion by 2031, at a CAGR of 6.7% over the forecast period. Growth is driven by the rising prevalence of chronic diseases requiring frequent or long-term intravenous treatments, such as cancer, cardiovascular disease, and kidney failure—along with increasing surgical volumes, hospital admissions, and emergency and critical-care needs. The introduction of safety-engineered devices, antimicrobial and antithrombogenic coatings, and improved catheter materials is enhancing patient safety and clinical efficiency, supporting broader adoption. A growing geriatric population, the expansion of hospital and home-care delivery models, and a strong emphasis on infection control and cost-effective treatment further accelerate demand worldwide.

At the same time, advances in non-invasive imaging—particularly ultrasound-guided vascular access—are improving first-attempt insertion success, reducing complications, and expanding the pool of patients who can be safely cannulated. Image-guided placement enables accurate assessment of vein suitability and early detection of complications, increasing procedural precision and the quality of patient outcomes. These capabilities are especially valuable for difficult-access patients and for longer-dwell devices such as midlines and peripherally inserted central catheters (PICCs), where reliable placement directly affects therapy continuity and infection risk.

To know about the assumptions considered for the study download the pdf brochure

In addition, the migration of infusion therapy toward outpatient clinics, ambulatory surgery centers, and home healthcare is reshaping demand. Providers increasingly require devices that allow rapid placement, lower infection risk, and reduced training burden, alongside accessories—securement dressings, disinfecting caps, and needle-free connectors—that protect access sites across care transitions. Digital transformation through smart infusion systems and data-driven protocols is reinforcing this shift, as health systems prioritize value-based care, longer device dwell times, and standardized, auditable vascular access programs.

Major players in the vascular access device market include Becton, Dickinson and Company (US), Teleflex Incorporated (US), Terumo Corporation (Japan), ICU Medical, Inc. (US), and B. Braun (Germany). These companies offer comprehensive portfolios spanning peripheral intravenous catheters, midlines, PICCs, central venous catheters, implantable ports, intraosseous access systems, and supporting accessories. Their solutions emphasize infection prevention, safety-engineered designs, ultrasound-guided placement, and longer dwell times, enabling secure drug, fluid, blood, and nutrition delivery across hospitals, clinics, and home-care settings. Continued investment in antimicrobial and antithrombogenic technologies, integrated insertion systems, and clinician training supports modernization of vascular access workflows and reduction of catheter-related complications.

In April 2026, Becton, Dickinson and Company (BD) launched the BD CentroVena One Insertion System, described as the first all-in-one central venous catheter (CVC) insertion device on the market. The system consolidates the introducer needle, syringe, guidewire, and catheter into a single device to simplify central-line placement, received FDA 510(k) clearance, and entered the FDA Safer Technologies Program, marking BD's entry into the central-line segment with a focus on workflow simplification and patient safety in acute settings.

In October 2025, B. Braun expanded its vascular access portfolio with a next-generation central venous catheter featuring advanced antithrombotic and antimicrobial coatings, designed to reduce catheter-related bloodstream infections (CRBSIs) in high-risk patients, including those in intensive care and oncology settings. The launch reinforced the industry's continued shift toward infection-resistant device technologies for long-dwell central access.

Becton, Dickinson and Company (BD)

Becton, Dickinson and Company (US) is a leading global medical technology company focused on advancing healthcare through medical discovery, diagnostics, and delivery of care. The company holds a dominant position in vascular access, anchored by an extensive portfolio that was significantly strengthened through its acquisition of C. R. Bard. In the vascular access domain, BD offers closed peripheral IV catheter systems such as BD Nexiva; ultrasound-guided midline catheters such as BD PowerGlide Pro for extended peripheral therapy; PICCs; implantable ports; and a broad range of securement and infusion accessories. Its closed, integrated designs support longer dwell times and reduced blood exposure and needlestick risk, while its midline systems enable guidewire-assisted placement to improve insertion success. BD continues to advance its “one-stick hospital stays” vision and vascular access management programs, serving hospitals, clinics, and home-care providers across the Americas, Europe, the Middle East and Africa, and Asia Pacific.

Teleflex Incorporated

Teleflex Incorporated (US) is a global provider of medical technologies focused on critical care, surgery, and vascular access, marketing many of its access products under the Arrow brand. The company is particularly strong in acute and critical-care environments, offering a wide range of central venous catheters, PICCs, midlines, and pressure-injectable catheters, alongside emergency intraosseous access through the Arrow EZ-IO system, which enables vascular access in approximately ten seconds with high first-attempt success. Its antimicrobial-impregnated short-term CVCs, such as Arrowg+ard Blue Plus, use chlorhexidine and silver-sulfadiazine technology to suppress microbial colonization and reduce catheter-related bloodstream infections. Teleflex prioritizes clinical needs and physician-friendly design, and it has expanded its access and intervention capabilities through new product launches and strategic acquisitions, strengthening its presence across both developed and developing hospital markets.

Market Ranking

In 2025, the vascular access device market was competitive, with Becton, Dickinson and Company (US), Teleflex Incorporated (US), Terumo Corporation (Japan), ICU Medical, Inc. (US), and B. Braun (Germany) collectively accounting for approximately 65–70% of the market. As healthcare systems intensified their focus on infection prevention, patient safety, and cost-effective care, vendors accelerated innovation across safety-engineered devices, antimicrobial and antithrombogenic coatings, ultrasound-guided insertion, and integrated insertion systems.

1. Becton, Dickinson, and Company led the market through its broad peripheral and central access portfolio—including BD Nexiva closed PIVC systems and BD PowerGlide Pro midlines—supported by its scale, GPO relationships, and entry into the central-line segment with the BD CentroVena One Insertion System.
2. Teleflex strengthened its position in acute and critical care through the Arrow brand, emphasizing intraosseous access (Arrow EZ-IO), antimicrobial CVCs (Arrowg+ard Blue Plus), and pressure-injectable catheters, while expanding through targeted acquisitions.
3. Terumo Corporation strengthened its vascular access portfolio through advanced peripheral IV catheters, central venous catheters, and infusion systems. Its Surflo and Radifocus product lines emphasize atraumatic needle technology, safety-engineered designs, and high-performance catheter materials for improved clinical outcomes and patient comfort.
4. ICU Medical, Inc. expanded its infusion therapy and vascular access portfolio through the acquisition of Smiths Medical, strengthening its offerings in central venous catheters, needle-free connectors, and vascular access devices. Its Clave, PowerPICC, and Arrow product families support safe vascular access with infection prevention features and reliable infusion performance.
5. B. Braun SE maintains a comprehensive vascular access portfolio comprising peripheral IV catheters, central venous catheters, PICCs, and safety IV cannulas. Its Introcan Safety, Certofix, and Vasofix product lines incorporate safety-engineered needle protection, antimicrobial options, and ergonomic designs to enhance clinician safety, procedural efficiency, and patient care.

Across the competitive landscape, vendors have increasingly focused on infection prevention, safety-engineered designs, ultrasound-guided placement, and integrated insertion systems to differentiate on clinical outcomes, dwell time, and total cost of care. These developments reflect the growing maturity of the VAD market as providers continue to invest in safer, more reliable vascular access to support oncology, dialysis, critical-care, and outpatient therapy.

Related Reports:

Vascular Access Device Market Type [Central, Peripheral (Venous {PIVC, Midline}, Arterial), Intraosseous], Route of Insertion, Application [Chemotherapy, Fluid Administration, Diagnostic], End User [Hospital (Public, Private)] - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]